The FDA has approved Keveyis (dichlorphenamide) 50 mg tablets, from Taro Pharma, for the treatment of primary hyperkalemic and hypokalemic...
Strongbridge Biopharma plc,, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with...